Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT00038623
- Phase
- PHASE2
- Status
- Completed
Conditions
- Lymphoma, Mantle-Cell
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Yttrium-ibritumomab (Zevalin) — DRUGAfter Rituximab infusion, 111\^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
- Rituximab — DRUG250 mg/m\^2 in the vein over 6 to 8 hours on Day 1.
Study Details
Study of Yttrium-ibritumomab (Zevalin) For the treatment of Patients with Relapsed \& Refractory Mantle Cell Lymphoma
Key Dates
- Start date
- Apr 30, 2002
- Status verified
- Oct 2011
- Primary completion
- Dec 31, 2007
- Completion
- Feb 28, 2010
Study Design
- Enrollment
- 35 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Yttrium-ibritumomab (Zevalin)After Rituximab infusion (250 mg/m\^2 intravenous) on Day 1, 111\^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
Primary Outcome Measure
Number of Participants with Objective tumor response [ Time Frame: Followed for 4 years or until disease progression ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| MD Anderson Cancer Center | Houston | Texas | 77030 | - |
Find similar trials in Houston, TX
By research site